Cash and Marketable Securities

12 Months Ended

Dec. 31, 2023

Cash and Cash Equivalents [Abstract]

Cash and Marketable Securities:

The components of our investments as of December 31, 2023 are as follows (in millions):


	Cash & Cash Equivalents		Restricted Cash		Restricted Marketable Securities		Total
Cash	$	69.1	$	35.1	$	—	$	104.2
Equity securities	—		—		126.2		126.2

Total	$	69.1	$	35.1	$	126.2	$	230.4

The components of our investments as of December 31, 2022 are as follows (in millions):


	Cash & Cash Equivalents		Restricted Cash		Restricted Marketable Securities		Total
Cash	$	21.8	$	31.6	$	—	$	53.4
Equity securities	—		—		110.0		110.0

Total	$	21.8	$	31.6	$	110.0	$	163.4

Restricted Cash—

Restricted cash consisted of the following (in millions):


	As of December 31,
	2023		2022
Current:
Affiliate cash	$	17.7	$	12.9
Self-insured captive funds	17.1		17.3

Other	0.3		1.4
Total restricted cash	$	35.1	$	31.6

Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture’s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note 11, Self-Insured Risks. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.

The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.

Marketable Securities—

Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health’s professional liability, workers’ compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December 31, 2023, $37.6 million of restricted marketable securities are included in Other current assets and $88.6 million are included in Other long-term assets in the consolidated balance sheet. As of December 31, 2022, $30.9 million of restricted marketable securities are included in Other current assets and $79.1 million are included in Other long-term assets in the consolidated balance sheet. During the years ended December 31, 2023, 2022, and 2021, $1.3 million, $(7.4) million, and $0.6 million, respectively, of unrealized net gains (losses) were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.